Importance of Cancer Research for Latinos in South Texas | The New Cancer Quest
Find out how Mays Cancer Center is leading cancer research for Latinos and why it’s important for the future of cancer care in South Texas.
Find out how Mays Cancer Center is leading cancer research for Latinos and why it’s important for the future of cancer care in South Texas.
Hear what one expert from Mays Cancer Center is saying about the UT Health San Antonio’s Multispecialty and Research Hospital coming to #SanAntonio in late 2024 to meet the community’s #cancer care needs.
Hear medical oncologist, Kate Lathrop, MD, share the value of offering clinical trials to patients and the potential it has to playing a key role in survivorship.
Chief Medical Officer Mark Bonnen, MD, talks about an innovative device used at Mays Cancer Center to help personalize a patient’s radiation treatment and decrease the amount of radiation exposure.
Kate Lathrop, MD, highlights how the cancer center has shifted the paradigm in care for breast cancer patients and the positive impact it has made in their lives.
The goal of this study is to develop and pilot test a multi-communication approach to improve informed decision-making about cancer Clinical Trials (CTs) participation by increasing awareness of CTs and Mays Cancer Center (MCC) services (treatment care capacities, reputation and resources), positive attitudes towards CTs, self-efficacy and intentions to consider CTs as an appropriate treatment option for cancer (intention to participate) among patients attending the MCC (clinic-based setting) and the general public in selected Bexar County areas (community-based settings).
The primary objective of this study is to compare Assay results to diagnoses determined by currently accepted standards for lung cancer detection. This will be accomplished by analysis of sputum samples from three cohorts including healthy Participants, high risk Participants, and cancer patient Participants using the Assay as developed in accordance with findings of bioAffinity protocol BA-001 to confirm assay results. Adjustments will be made as necessary to finalize Assay design for clinical trials and commercialization. The secondary objective of this study is to determine optimum methods for collection of sputum samples. Three sputum collection methods used by high risk Participants will be compared. Individuals at high risk for lung cancer will be assigned to one of three sputum collection cohorts including (1) acapella® airway assist device under medical supervision to obtain a single sputum sample; (2) acapella® airway assist device to obtain a sputum sample over a three-day period, and (3) individuals who under medical supervision will collect a single sputum sample assisted by nebulization of between 0.9% to 10% hypertonic saline. Samples will be compared to determine the optimal collection method for sample analysis by CyPath® Lung.
The goal of this infrastructure grant is to establish and maintain a cohort of over 12,000 non-Hodgkin lymphoma (NHL) patients to support broad and cutting-edge research that identifies clinical (including co-morbid diseases), epidemiologic (including lifestyle and other exposures), host genetic, tumor, and treatment factors, as well as the interaction among these factors, on short and long-term outcomes. These efforts will identify new approaches to improve the survival and well-being of NHL patients.
This investigation is designed to be a two-arm, non-randomized prospective phase 2 study evaluating the impact of medical physicist patient intervention on the anxiety level and patient satisfaction of patients undergoing a course of radiation therapy. Our goal is to demonstrate that these interventions will have a significantly positive impact on the overall well-being of our oncology patients
We propose to test whether H1 and H2 clustering can distinguish patients responsive or resistant to the combination therapy with immunotherapy in a prospective clinical study.